Evidence map›Paper›PMID 36388442›Full record

ArticleIndian journal of anaesthesia2022

A randomised controlled trial of high-flow nasal oxygen versus non-rebreathing oxygen face mask therapy in acute hypoxaemic respiratory failure.

Bhargavi Thota, Aloka Samantaray, B Vengamma, Hanumantha Rao Mangu, Mohan Alladi, Usha Kalawat

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of anaesthesia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Risk of bias in published randomised controlled trials.Indian journal of anaesthesia · 2023
    Article
  7. Trends in research inIndian journal of anaesthesia · 2023
    Article
  8. Thrust on airway research - Exploring the publications.Indian journal of anaesthesia · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bhargavi ThotaDepartment of Anaesthesiology and CCM, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Aloka SamantarayDepartment of Anaesthesiology and CCM, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
B VengammaDepartment of Neurology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Hanumantha Rao ManguDepartment of Anaesthesiology and CCM, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Mohan AlladiDepartment of Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Usha KalawatDepartment of Clinical Virology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.
Sri Venkateswara Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: A major limitation to providing oxygen therapy by high flow nasal oxygen (HFNO) delivery devices is its availability and therefore as an alternative many clinicians use a standard non rebreathing face mask (NRBM) in order to oxygenate their patients where low-flow nasal oxygen or simple facemask oxygen is not providing adequate respiratory support to achieve the target peripheral oxygen saturation (SpO Methods: In this prospective open labelled study, 122 COVID-19 patients presenting with acute hypoxaemic respiratory failure (AHRF) were randomised to receive either HFNO or NRBM to achieve the target SpO Results: The device failure rate was significantly higher in HFNO group (39% versus 21%, P = 0.030). Oxygen support with NRBM resulted in a reduced all mortality rate over HFNO (26.2% versus 45%) but the mortality rate after treatment failure in either group (HFNO or NRBM) remained high (91% versus 92%). Conclusion: Oxygen support with NRBM results in both reduced device failure rate and higher survival among patients of COVID-19 with AHRF.

Indexed as

Acute hypoxaemic respiratory failureCOVID-19high flow nasal oxygenmortalitynon-rebreathing masktreatment failure

Identifiers

PMID36388442
PMCPMC9662091
OpenAlexW4296066018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.